A group from Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, China has reported that T-antigen could be a biomarker of progression-free survival (PFS) in patients with glioblastoma (GMB).
https://onlinelibrary.wiley.com/doi/10.1002/acn3.52082
They concluded from studies using Lectin microarrays that serum Jacalin-probed T-antigen levels, which were positively correlated with those in GBM tissues, may be used as a non-invasive biomarker of PFS, predicting GBM recurrences.
However, blog author thinks that their conclusion is problematic, because the glycan binding specificity of Jacalin is quite broad covering GlcNAcβ1-3GalNAc (Core3), Siaα2-3Galβ1-3GalNAc (sialyl T), Galβ1-3GalNAc (T-antigen), α-GalNAc (Tn-antigen), and also PNA could not discriminate glioblastoma so well, although it has high binding specificity to Galβ1-3GalNAc (T-antigen).
